ARTLifeLine: Assisted Reproduction Technology (ART) Family Health and Development Trajectory Cohort (ARTLL)
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Jan 19, 2025
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
1. Recent Research Objectives (Within Five Years):
Build a risk prediction model for reproductive women and children in assisted reproduction, and identify potential molecular markers with high predictive value to provide epidemiological evidence clues for further basic mechanism research.
Analyze the health status of natural conception versus assisted reproduction pregnant women and children, growth and developmental curves of fetuses during pregnancy, and early neurobehavioral development levels of children after birth.
2. Medium to Long-Term Research Objectives (Future Research D...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • (1) Previous or planned IVF treatment; (2) paper or electronic medical records during fertility treatment are available; (3) Obtain informed consent from the research subject or guardian of the minor.
- Exclusion Criteria:
- • (1) Other assisted reproductive treatment techniques that exclude in vitro fertilization, including guided intercourse, ovulation induction, artificial insemination, etc.; (2) refusal of enrollment; (3) withdraw or abort the study at any time and for any reason.
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Beijing, Beijing, China
Patients applied
Trial Officials
Jie Qiao, PhD
Study Chair
Peking University Third Hospital
Rong Li, PhD
Study Director
Peking University Third Hospital
Wei Yuan, PhD
Principal Investigator
Peking University Third Hospital
Tongyan Han, PhD
Principal Investigator
Peking University Third Hospital
Liying Yan, PhD
Study Director
Peking University Third Hospital
Yuanyuan Wang, PhD
Principal Investigator
Peking University Third Hospital
Rui / Yang, PhD
Principal Investigator
Peking University Third Hospital
Xiaohui / Zhu, PhD
Principal Investigator
Peking University Third Hospital
Lian / Chen, PhD
Principal Investigator
Peking University Third Hospital
Meihua / Piao, PhD
Principal Investigator
Peking University Third Hospital
Yunpu / Cui, PhD
Principal Investigator
Peking University Third Hospital
Yanan / Tang, PhD
Principal Investigator
Peking University Third Hospital
Chunling / Huang, PhD
Principal Investigator
Peking University Third Hospital
Chunmei / Zhang, PhD
Principal Investigator
Peking University Third Hospital
Linlin / Wang, PhD
Principal Investigator
Peking University Third Hospital
Ningning / Pan, PhD
Principal Investigator
Peking University Third Hospital
Huifeng Shi, PhD
Principal Investigator
Peking University Third Hospital
Tianchen / Wu, PhD
Principal Investigator
Peking University Third Hospital
Wanning / Qiu, PhD
Principal Investigator
Peking University Third Hospital
Jinfang / Yuan, PhD
Principal Investigator
Peking University Third Hospital
Hui / Zhang, MD
Principal Investigator
Peking University Third Hospital
Qingqing Wang
Principal Investigator
Peking University Third Hospital
Meng Qin
Principal Investigator
Peking University Third Hospital
Ying Kuo
Principal Investigator
Peking University Third Hospital
Wenxi Zhang
Principal Investigator
Peking University Third Hospital
Shuo Guan
Principal Investigator
Peking University Third Hospital
Siming Jiang
Principal Investigator
Peking University Third Hospital
Fei Kong
Principal Investigator
Peking University Third Hospital
Tian Tian, PhD
Principal Investigator
Peking University Third Hospital
Lixue Chen
Principal Investigator
Peking University Third Hospital
Yu Fu
Principal Investigator
Peking University Third Hospital
Fang Liu
Principal Investigator
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported